Health ❯ Clinical Trials

Drug Development

Regulatory Affairs Phase 3 Trials Eli Lilly FDA Approval Combination Therapy Cancer Treatments Regulatory Approval Regulatory Approvals Hormonal Research Human Health Efficacy Studies Phase I Trials Preclinical Testing Male Contraceptive Trials Neurological Disorders Therapeutic Uses Oncology Pilot Studies Antiviral Therapies SARM1 Therapeutics India Novo Nordisk Phase 1 Trials Therapeutic Evaluation Pharmacokinetics Safety Trials Male Birth Control Combination Therapies Safety Testing Asthma Medications Preclinical Models Patient Outcomes Pre-clinical Studies GLP-1 Drugs Manufacturing Facilities Research Institutions PMX205 Semaglutide Amivantamab Patient-Derived Organoids Weight Loss Inhibitors Phase 2 Trials IRE1α Inhibitors Cancer Drugs Repurposing Drugs Biomarkers Pipeline Programs Precision Medicine Rare Diseases

Low-Dose THC Paired With Celecoxib Improves Cognition and Alzheimer’s Pathology in Mice

The team cites existing FDA approvals as a potential shortcut to clinical trials.

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Immune Cell Stress Switch Implicated in Chemo Neuropathy, With Existing Inhibitors Poised for Tests

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

Blocking C5aR1 Preserves Memory in Mouse Brain Radiotherapy Without Undermining Tumor Control

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

Kidney Organoids Reveal NFκB‑Linked AAV2 Toxicity, With Bardoxolone Methyl Mitigating Damage

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

Leukemia-on-a-Chip Enables Rapid, Scalable CAR T-Cell Therapy Screening

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Silencing Enzyme Gene Boosts NK Cell Cancer-Fighting Power

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials